BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 18326813)

  • 1. Simultaneously targeting CD45 significantly increases cytotoxicity of the anti-CD33 immunoconjugate, gemtuzumab ozogamicin, against acute myeloid leukemia (AML) cells and improves survival of mice bearing human AML xenografts.
    Walter RB; Boyle KM; Appelbaum FR; Bernstein ID; Pagel JM
    Blood; 2008 May; 111(9):4813-6. PubMed ID: 18326813
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CD33-directed therapy with gemtuzumab ozogamicin in acute myeloid leukemia: progress in understanding cytotoxicity and potential mechanisms of drug resistance.
    Linenberger ML
    Leukemia; 2005 Feb; 19(2):176-82. PubMed ID: 15592433
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro experimental (211)At-anti-CD33 antibody therapy of leukaemia cells overcomes cellular resistance seen in vivo against gemtuzumab ozogamicin.
    Petrich T; Korkmaz Z; Krull D; Frömke C; Meyer GJ; Knapp WH
    Eur J Nucl Med Mol Imaging; 2010 May; 37(5):851-61. PubMed ID: 20107790
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preliminary results of the safety of immunotherapy with gemtuzumab ozogamicin following reduced intensity allogeneic stem cell transplant in children with CD33+ acute myeloid leukemia.
    Roman E; Cooney E; Harrison L; Militano O; Wolownik K; Hawks R; Foley S; Satwani P; Unal E; Bhatia M; Bradley B; Del Toro G; George D; Garvin J; van de Ven C; Cairo MS
    Clin Cancer Res; 2005 Oct; 11(19 Pt 2):7164s-7170s. PubMed ID: 16203817
    [TBL] [Abstract][Full Text] [Related]  

  • 5. AKT signaling as a novel factor associated with in vitro resistance of human AML to gemtuzumab ozogamicin.
    Rosen DB; Harrington KH; Cordeiro JA; Leung LY; Putta S; Lacayo N; Laszlo GS; Gudgeon CJ; Hogge DE; Hawtin RE; Cesano A; Walter RB
    PLoS One; 2013; 8(1):e53518. PubMed ID: 23320091
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of CD33 expression levels and ITIM-dependent internalization on gemtuzumab ozogamicin-induced cytotoxicity.
    Walter RB; Raden BW; Kamikura DM; Cooper JA; Bernstein ID
    Blood; 2005 Feb; 105(3):1295-302. PubMed ID: 15454492
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gemtuzumab ozogamicin, a potent and selective anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia.
    Hamann PR; Hinman LM; Hollander I; Beyer CF; Lindh D; Holcomb R; Hallett W; Tsou HR; Upeslacis J; Shochat D; Mountain A; Flowers DA; Bernstein I
    Bioconjug Chem; 2002; 13(1):47-58. PubMed ID: 11792178
    [TBL] [Abstract][Full Text] [Related]  

  • 8. What happened to anti-CD33 therapy for acute myeloid leukemia?
    Jurcic JG
    Curr Hematol Malig Rep; 2012 Mar; 7(1):65-73. PubMed ID: 22109628
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytotoxic activity of gemtuzumab ozogamicin (Mylotarg) in acute myeloid leukemia correlates with the expression of protein kinase Syk.
    Balaian L; Ball ED
    Leukemia; 2006 Dec; 20(12):2093-101. PubMed ID: 17051243
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I/II study of humanized anti-CD33 antibody conjugated with calicheamicin, gemtuzumab ozogamicin, in relapsed or refractory acute myeloid leukemia: final results of Japanese multicenter cooperative study.
    Kobayashi Y; Tobinai K; Takeshita A; Naito K; Asai O; Dobashi N; Furusawa S; Saito K; Mitani K; Morishima Y; Ogura M; Yoshiba F; Hotta T; Bessho M; Matsuda S; Takeuchi J; Miyawaki S; Naoe T; Usui N; Ohno R
    Int J Hematol; 2009 May; 89(4):460-469. PubMed ID: 19360457
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multidrug resistance protein attenuates gemtuzumab ozogamicin-induced cytotoxicity in acute myeloid leukemia cells.
    Walter RB; Raden BW; Hong TC; Flowers DA; Bernstein ID; Linenberger ML
    Blood; 2003 Aug; 102(4):1466-73. PubMed ID: 12689934
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Upfront use of gemtuzumab ozogamicin in young children with CD33-positive AML.
    Sayar D; Burstein Y; Bielorai B; Toren A; Dvir R
    Pediatr Blood Cancer; 2010 Jul; 55(1):183-5. PubMed ID: 20310000
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunotherapy for acute myeloid leukemia.
    Jurcic JG
    Curr Oncol Rep; 2005 Sep; 7(5):339-46. PubMed ID: 16091194
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Antibody directed therapy for leukemia].
    Takeshita A; Naito K; Ohno R
    Nihon Rinsho; 2002 Mar; 60(3):517-24. PubMed ID: 11904967
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antibody-based therapy of acute myeloid leukemia with gemtuzumab ozogamicin.
    Cowan AJ; Laszlo GS; Estey EH; Walter RB
    Front Biosci (Landmark Ed); 2013 Jun; 18(4):1311-34. PubMed ID: 23747885
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gemtuzumab ozogamicin: an anti-CD33 immunoconjugate for the treatment of acute myeloid leukaemia.
    Stasi R
    Expert Opin Biol Ther; 2008 Apr; 8(4):527-40. PubMed ID: 18352855
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CD33 expression and P-glycoprotein-mediated drug efflux inversely correlate and predict clinical outcome in patients with acute myeloid leukemia treated with gemtuzumab ozogamicin monotherapy.
    Walter RB; Gooley TA; van der Velden VH; Loken MR; van Dongen JJ; Flowers DA; Bernstein ID; Appelbaum FR
    Blood; 2007 May; 109(10):4168-70. PubMed ID: 17227830
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Phase I Study of Reduced-Intensity Conditioning and Allogeneic Stem Cell Transplantation Followed by Dose Escalation of Targeted Consolidation Immunotherapy with Gemtuzumab Ozogamicin in Children and Adolescents with CD33+ Acute Myeloid Leukemia.
    Zahler S; Bhatia M; Ricci A; Roy S; Morris E; Harrison L; van de Ven C; Fabricatore S; Wolownik K; Cooney-Qualter E; Baxter-Lowe LA; Luisi P; Militano O; Kletzel M; Cairo MS
    Biol Blood Marrow Transplant; 2016 Apr; 22(4):698-704. PubMed ID: 26785332
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ab therapy of AML: native anti-CD33 Ab and drug conjugates.
    Jurcic JG
    Cytotherapy; 2008; 10(1):7-12. PubMed ID: 17917880
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel AML-selective TRAIL fusion protein that is superior to Gemtuzumab Ozogamicin in terms of in vitro selectivity, activity and stability.
    ten Cate B; Bremer E; de Bruyn M; Bijma T; Samplonius D; Schwemmlein M; Huls G; Fey G; Helfrich W
    Leukemia; 2009 Aug; 23(8):1389-97. PubMed ID: 19262596
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.